UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection

Journal of hepatology, 2015-03, Vol.62 (3), p.533-540

2015

Link zum Volltext

Verfügbarkeit prüfen

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Journal of hepatology, 2017-08, Vol.67 (2), p.370-398

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C

Annals of hepatology, 2016-07, Vol.15 (4), p.512-523

2016

Link zum Volltext

Verfügbarkeit prüfen

Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant

Annals of hepatology, 2017-05, Vol.16 (3), p.375-381

2017

Link zum Volltext

Verfügbarkeit prüfen

Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis

Journal of hepatology, 2016-10, Vol.65 (4), p.741-747

2016

Link zum Volltext

Verfügbarkeit prüfen

Liver abnormalities in the immunosuppressed

Baillière's best practice & research. Clinical gastroenterology, 2013-08, Vol.27 (4), p.597-618

2013

Link zum Volltext

Verfügbarkeit prüfen

Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial

Journal of hepatology, 2016-07, Vol.65 (1), p.33-39

2016

Link zum Volltext

Verfügbarkeit prüfen

Treatment of chronic hepatitis C virus infection after liver transplantation

Digestive and liver disease, 2013-09, Vol.45, p.S349-S354

2013

Link zum Volltext

Verfügbarkeit prüfen

Global Epidemiology of HCV Subtypes and Resistance-associated Substitutions Evaluated by Sequencing-Based Subtype Analyses

Journal of hepatology, 2017-08, Vol.67 (2), p.224-236

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection

Gastroenterology (New York, N.Y. 1943), 2015-11, Vol.149 (6), p.1462-1470

2015

Link zum Volltext

Verfügbarkeit prüfen

Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis

Journal of hepatology, 2017-08, Vol.67 (2), p.263-271

2017

Link zum Volltext

Verfügbarkeit prüfen

Massive Gastrointestinal Bleed in a Patient With Primary Sclerosing Cholangitis

Gastroenterology (New York, N.Y. 1943), 2011-05, Vol.140 (5), p.e7-e8

2011

Link zum Volltext

Verfügbarkeit prüfen

Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C

Gastroenterology (New York, N.Y. 1943), 2014-03, Vol.146 (3), p.744-753.e3

2014

Link zum Volltext

Verfügbarkeit prüfen

812e The Use of Sofosbuvir and Velpatasvir is Associated With High Efficacy and Improvement in Patient-Reported Outcomes in Patients with Genotype 1, 2, 4, 5 and 6 Chronic Hepatitis C: Results from the ASTRAL-1 Clinical Trial

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S1267-S1268

2016

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis B (HBV) Viral Suppression is Independently Associated with Better Patient-Reported Outcomes (PROS)

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S1085-S1085

2017

Link zum Volltext

Verfügbarkeit prüfen

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection

Journal of hepatology, 2015-06, Vol.62 (6), p.1246-1255

2015

Link zum Volltext

Verfügbarkeit prüfen

Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Positive Patients: A Global Phase 3 Study

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S1085-S1086

2017

Link zum Volltext

Verfügbarkeit prüfen

Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S1061-S1061

2017

Link zum Volltext

Verfügbarkeit prüfen

Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

Journal of hepatology, 2016

2016

Link zum Volltext

Verfügbarkeit prüfen

A Phase 3 Study of Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-negative, Chronic Hepatitis B (CHB): Week 48 Efficacy and Safety Results

Clinical gastroenterology and hepatology, 2017, Vol.15 (1), p.e44-e44

2017

Link zum Volltext

Verfügbarkeit prüfen

Su1413 Sof/VEL for 12 Weeks Results in High SVR 12 Rates in Subjects With Negative Predictors of Response to Treatment: An Integrated Analysis of Efficacy Fron the ASTRAL-1, ASTRAL-2 and ASTRAL-3 Studies

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S1092-S1092

2016

Link zum Volltext

Verfügbarkeit prüfen

Sa1637 High Efficacy of Ledipasvir/Sofosbuvir Plus Ribavirin Among Patients With Decompensated Cirrhosis Who Underwent Liver Transplant During Participation in the SOLAR-1 and SOLAR-2 Studies

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S1083-S1083

2016

Link zum Volltext

Verfügbarkeit prüfen

Su1060 Faldaprevir Plus Pegylated Interferon/Ribavirin Did Not Increase Anaemia Compared With Pegylated Interferon/Ribavirin in HCV Genotype-1, Treatment-Naïve Patients: Pooled Analysis of Phase III Studies

Gastroenterology (New York, N.Y. 1943), 2014-05, Vol.146 (5), p.S-977-S-977

2014

Link zum Volltext

Verfügbarkeit prüfen

Tu2039 TURQUOISE-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults with Compensated Cirrhosis Treated with ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV)

Gastroenterology (New York, N.Y. 1943), 2014-05, Vol.146 (5), p.S-903-S-903

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 27

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Viral Hepatitis

ThemaGastroenterology And Hepatology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(15)
Gastroenterology & Hepatology
(13)
Life Sciences & Biomedicine
(13)
Science & Technology
(13)
Male
(10)
Female
(9)
Middle Aged
(9)
Antiviral Agents - Therapeutic Use
(8)
Adult
(7)
Antiviral Agents - Adverse Effects
(7)
Drug Therapy, Combination
(7)
Genotype
(7)
Hepacivirus - Genetics
(7)
Hepatitis C, Chronic - Drug Therapy
(6)
Treatment Outcome
(6)
Aged
(5)
Antiviral Agents - Administration & Dosage
(5)
Hepacivirus - Drug Effects
(5)
Ribavirin - Therapeutic Use
(5)

14 weitere anzeigen...

Weniger anzeigen...

Kollektion

IngentaConnect Journals
(25)
IngentaConnect
(25)
Elsevier ScienceDirect Journals Complete
(25)
MEDLINE
(15)
Single Journals
(14)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(9)
Journals@Ovid Complete
(9)
EZB Electronic Journals Library
(2)

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C

Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant

Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis

Liver abnormalities in the immunosuppressed

Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial

Treatment of chronic hepatitis C virus infection after liver transplantation

Global Epidemiology of HCV Subtypes and Resistance-associated Substitutions Evaluated by Sequencing-Based Subtype Analyses

Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection

Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir In Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Massive Gastrointestinal Bleed in a Patient With Primary Sclerosing Cholangitis

Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C

812e The Use of Sofosbuvir and Velpatasvir is Associated With High Efficacy and Improvement in Patient-Reported Outcomes in Patients with Genotype 1, 2, 4, 5 and 6 Chronic Hepatitis C: Results from the ASTRAL-1 Clinical Trial

Hepatitis B (HBV) Viral Suppression is Independently Associated with Better Patient-Reported Outcomes (PROS)

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection

Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Positive Patients: A Global Phase 3 Study

Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study

Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

A Phase 3 Study of Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-negative, Chronic Hepatitis B (CHB): Week 48 Efficacy and Safety Results

Su1413 Sof/VEL for 12 Weeks Results in High SVR 12 Rates in Subjects With Negative Predictors of Response to Treatment: An Integrated Analysis of Efficacy Fron the ASTRAL-1, ASTRAL-2 and ASTRAL-3 Studies

Sa1637 High Efficacy of Ledipasvir/Sofosbuvir Plus Ribavirin Among Patients With Decompensated Cirrhosis Who Underwent Liver Transplant During Participation in the SOLAR-1 and SOLAR-2 Studies

Su1060 Faldaprevir Plus Pegylated Interferon/Ribavirin Did Not Increase Anaemia Compared With Pegylated Interferon/Ribavirin in HCV Genotype-1, Treatment-Naïve Patients: Pooled Analysis of Phase III Studies

Tu2039 TURQUOISE-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults with Compensated Cirrhosis Treated with ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV)

Aktive Filter

Suchergebnisse filtern